| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-24 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.150 | -0.140 | 0.0100 | ||||
| REV | 270.000K | 200.000K | -70.000K |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Vaxart (NASDAQ: VXRT) through any online brokerage.
Other companies in Vaxart’s space includes: Humacyte (NASDAQ:HUMA), bluebird bio (NASDAQ:BLUE), Precigen (NASDAQ:PGEN), Pharming (NASDAQ:PHAR) and Mesoblast (NASDAQ:MESO).
The latest price target for Vaxart (NASDAQ: VXRT) was reported by Cantor Fitzgerald on November 2, 2021. The analyst firm set a price target for 15.00 expecting VXRT to rise to within 12 months (a possible 226.80% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Vaxart (NASDAQ: VXRT) is $4.59 last updated Fri Jan 28 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Vaxart.
Vaxart’s $Q4 earnings are confirmed for after-market on February 24, 2022.
There is no upcoming split for Vaxart.
Vaxart is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.